$WST Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $2.66 up 35.71% YoY
• Reported revenue of $874.5M up 8.69% YoY
• West Pharmaceutical Services increased full-year 2026 net sales guidance to $3.41B to $3.42B and adjusted-diluted EPS guidance to $9.38 to $9.48, both increased from prior guidance.